Global Stem Cell Assay (Viability, Differentiation, Cell Identification …EconoTimesThe global stem cell assay market is expected to reach USD 1,363.3 million by 2021 from USD 536.6 million in 2016, at a CAGR of 20.5% from 2016 to 2021.$1.36 Billion … Continue reading
Global Stem Cell Assay (Viability, Differentiation, Cell Identification) Market Growth at CAGR of 20.5%, 2016-2021GlobeNewswire (press release)Factors such as high prevalence of chronic diseases, increasing investment in research related activities, an… Continue reading
Stem Cell Assay (Viability, Differentiation, Cell Identification) Market 2016-2021: $1.3 Billion Market Drivers …Business Wire (press release)The global stem cell assay market is expected to reach USD 1,363.3 million by 2021 from USD 536.6 million in… Continue reading
PR Web (press release)Former Texas Governor Rick Perry Appointed to Celltex Therapeutics Board of DirectorsPR Web (press release)As the 47th and longest-serving governor of the Lone Star State, Perry championed the advancement of adult stem cell therap… Continue reading
|
RT-IMRI guidance improves safety, efficacy of stem cell treatment for Parkinson’s disease
News-Medical.net In a study using Real-time intraoperative magnetic resonance imaging (RT-IMRI) to guide the transplantation of induced pluripotent stem cell (iPSC)-derived neurons into the brains of non-human primates modeled with Parkinson’s disease, researchers … |
|
RT-IMRI guidance improves safety, efficacy of stem cell treatment for Parkinson’s disease
News-Medical.net In a study using Real-time intraoperative magnetic resonance imaging (RT-IMRI) to guide the transplantation of induced pluripotent stem cell (iPSC)-derived neurons into the brains of non-human primates modeled with Parkinson’s disease, researchers … |
|
Prima to Present at 2016 Society for Immunotherapy of Cancer Conference
Yahoo Finance SYDNEY, AUSTRALIA–(Marketwired – Oct 12, 2016) – Prima BioMed Ltd ( ASX : PRR ) ( NASDAQ : PBMD ) (“Prima”) announces that the submission titled “LAG-3Ig (IMP321) in combination with anti-PD-1 therapy” has been accepted for a presentation at the … |